Multiple insiders have executed 6 significant purchases totaling over $421,000 in the past month, demonstrating remarkable confidence in $TriSalus Life Sciences (TLSI.US)$. This insider accumulation comes alongside impressive Q4 results showing 44% YoY revenue growth to $8.3M and full-year 2024 revenue up 59% to $29.4M.  🚀Worth watching this emerging player in the $4.56B cancer therapeutics market! Read our complete analysis: TriSalus Life Sciences Because Its Approach to Cancer Therapy Stands Out | Investment Review
...

$Agios Pharmaceuticals (AGIO.US)$
Clinical Trial Breakthrough: Agios' Blood Disorder Drug Outperforms Placebo in Rare Pediatric Disease

$Agios Pharmaceuticals (AGIO.US)$
Agios Delivers Record PYRUKYND Growth as FDA Decision Looms: Q4 Earnings Deep Dive

🚨 This Week’s PDUFA:
$Humacyte (HUMA.US)$ : 🤔
⇨ Human Acellular Vessel (HAV)™
‣ Vascular Trauma
‣ PDUFA: 8/10/24 (BLA)
🗓️ Last Week’s AdCom & PDUFAs:
$Zevra Therapeutics (ZVRA.US)$ : Favorable AdCom 👍
🗳️ 11-5 votes in favor
⇨ Arimoclomol
‣ Niemann-Pick disease type C
‣ AdCom: 8/2/24 (NDA)
$Adaptimmune Therapeutics (ADAP.US)$ : Approved 🎉
⇨ TECELRA (afamitresgene autoleucel)
‣ Synovial sarcoma
‣ PDUFA: 8/4/24 (BLA)
$GlaxoSmithKline (GSK.US)$ : Approved 🎉
⇨ Jemperli
‣ Endometria...

$Agios Pharmaceuticals (AGIO.US)$
HOW MANY STUPID TRADERS HERE, LOSING AND STILL TRADING 🤔🤔🤔

$Agios Pharmaceuticals (AGIO.US)$
Bad Demon Trap = Xi Zor Gai 😏

$United Therapeutics (UTHR.US)$  Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$  Phase 3
$Liquidia (LQDA.US)$  Phase 3
$United Therapeutics (UTHR.US)$  Phase 3
$MorphoSys (MOR.US)$  Phase 3
$Immunocore (IMCR.US)$  Phase 3
$Crinetics (CRNX.US)$  Phase 3
$UroGen Pharma Ltd (URGN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$Capricor Therapeutics (CAPR.US)$  Phase 3
$Annexon (ANNX.US)$  Phase 3
$Lipocine (LPCN.US)$  Phase 3...